- Home
- ESAB vs BPMC Comparison
ESAB vs BPMC Comparison
Compare ESAB & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESAB
- BPMC
- Stock Information
- Founded
- ESAB 1904
- BPMC 2008
- Country
- ESAB United States
- BPMC United States
- Employees
- ESAB N/A
- BPMC N/A
- Industry
- ESAB Office Equipment/Supplies/Services
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- ESAB Industrials
- BPMC Health Care
- Exchange
- ESAB Nasdaq
- BPMC Nasdaq
- Market Cap
- ESAB 6.9B
- BPMC 5.8B
- IPO Year
- ESAB N/A
- BPMC 2015
- Fundamental
- Price
- ESAB $127.83
- BPMC $97.17
- Analyst Decision
- ESAB Buy
- BPMC Buy
- Analyst Count
- ESAB 8
- BPMC 21
- Target Price
- ESAB $136.13
- BPMC $124.05
- AVG Volume (30 Days)
- ESAB 278.6K
- BPMC 988.9K
- Earning Date
- ESAB 05-01-2025
- BPMC 05-01-2025
- Dividend Yield
- ESAB 0.25%
- BPMC N/A
- EPS Growth
- ESAB 16.34
- BPMC N/A
- EPS
- ESAB 4.43
- BPMC N/A
- Revenue
- ESAB $2,729,197,000.00
- BPMC $562,121,000.00
- Revenue This Year
- ESAB N/A
- BPMC $44.85
- Revenue Next Year
- ESAB $5.05
- BPMC $32.06
- P/E Ratio
- ESAB $26.53
- BPMC N/A
- Revenue Growth
- ESAB N/A
- BPMC 99.19
- 52 Week Low
- ESAB $88.54
- BPMC $73.04
- 52 Week High
- ESAB $135.97
- BPMC $121.90
- Technical
- Relative Strength Index (RSI)
- ESAB 63.88
- BPMC 59.54
- Support Level
- ESAB $120.56
- BPMC $87.03
- Resistance Level
- ESAB $124.96
- BPMC $104.86
- Average True Range (ATR)
- ESAB 3.98
- BPMC 3.86
- MACD
- ESAB 1.19
- BPMC 1.24
- Stochastic Oscillator
- ESAB 95.83
- BPMC 64.38
About ESAB ESAB Corporation
ESAB, spun off from Colfax in 2022, is a leading manufacturer of equipment and consumables used in welding, cutting, and joining applications. Alongside competitors Lincoln Electric and ITW's Miller brand, ESAB is one of the top three players in the welding space. ESAB generated roughly $2.7 billion in revenue in 2024.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.